Bromocriptine modulates P-glycoprotein function.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Biochemical and Biophysical Research Communications - BBRC

• Publication date

  1998-03-17

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1006/BBRC.1998.8289PMID 9514944
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Kinetics of the multidrug transporter (P-glycoprotein) and its reversal.

  1997cited by this paper
• Bromocriptine Transcriptionally Activates the Multidrug Resistance Gene (pgp2/mdr1b) by a Novel Pathway*

  1997cited by this paper
• Competitive and non-competitive inhibition of the multidrug-resistance-associated P-glycoprotein ATPase--further experimental evidence for a multisite model.

  1997cited by this paper
• Metabolite involvement in bromocriptine-induced prolactin inhibition in rats.

  1997cited by this paper
• Effects of steroids and verapamil on P-glycoprotein ATPase activity: progesterone, desoxycorticosterone, corticosterone and verapamil are mutually non-exclusive modulators.

  1996cited by this paper
• Role of P‐Glycoprotein in the Blood‐Brain Transport of Colchicine and Vinblastine

  1996cited by this paper
• Enzyme immunoassays for bromocriptine and its metabolites.

  1996cited by this paper
• Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.

  1995cited by this paper
• In vivo evidence for ATP-dependent and P-glycoprotein-mediated transport of cyclosporin A at the blood-brain barrier.

  1994cited by this paper
• Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators.

  1993cited by this paper
• The pharmacology of Parkinson's disease therapy: an update.

  1993cited by this paper
• Targeted disruption of the mouse mdr1b gene reveals that steroid hormones enhance mdr gene expression.

  1993cited by this paper
• Increased mdr-1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists.

  1993cited by this paper
• Absence of cooperativity for MgATP and verapamil effects on the ATPase activity of P-glycoprotein containing membrane vesicles.

  1993cited by this paper
• Biochemistry of multidrug resistance mediated by the multidrug transporter.

  1993cited by this paper
• Functional involvement of P-glycoprotein in blood-brain barrier.

  1992cited by this paper
• [Functional involvement of P-glycoprotein in blood-brain barrier].

  1992cited by this paper
• Amino acid substitutions in the sixth transmembrane domain of P-glycoprotein alter multidrug resistance.

  1992cited by this paper
• The multidrug resistance and cystic fibrosis genes have complementary patterns of epithelial expression.

  1992cited by this paper
• Differential expression of the mouse D2 dopamine receptor isoforms

  1991cited by this paper
• High-performance liquid chromatographic assay of bromocriptine in rat plasma and brain.

  1990cited by this paper
• Pharmacology of drugs that alter multidrug resistance in cancer.

  1990cited by this paper
• Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus.

  1989cited by this paper
• Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.

  1989cited by this paper
• The direct activation of human multidrug resistance gene (MDR1) by anticancer agents.

  1989cited by this paper
• The function of Gp170, the multidrug resistance gene product, in rat liver canalicular membrane vesicles.

  1989cited by this paper
• The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus.

  1988cited by this paper
• Transient electropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs.

  1988cited by this paper
• ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells.

  1988cited by this paper
• Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.

  1987cited by this paper
• Pharmacokinetics and pharmacodynamics of bromocriptine in the rat.

  1985cited by this paper
• Multiple receptors for dopamine

  1979cited by this paper

• Bromocriptine monotherapy overcomes prostate cancer chemoresistance in preclinical models

  2023cites this paper
• Bromocriptine therapy: Review of mechanism of action, safety and tolerability

  2022cites this paper
• Progestins as Anticancer Drugs and Chemosensitizers, New Targets and Applications

  2021cites this paper
• OATP1A2 and OATP2B1 are interacting with dopamine receptor agonists and antagonists.

  2020cites this paper
• The effects of dietary and herbal phytochemicals on drug transporters☆

  2017cites this paper
• Identification of cellular and molecular factors determining the response of cancer cells to six ergot alkaloids

  2015influential citation
• Targeting CNS transporters for treatment of neurodegenerative diseases.

  2014cites this paper
• The role of ABC and SLC transporters in the pharmacokinetics of dietary and herbal phytochemicals and their interactions with xenobiotics.

  2012cites this paper
• Bromocriptine enhances the uptake of 99mTc-MIBI in patients with hepatocellular carcinoma

  2012cites this paper
• Board-invited review: St. Anthony's Fire in livestock: causes, mechanisms, and potential solutions.

  2011cites this paper
• Interactions of dietary phytochemicals with ABC transporters: possible implications for drug disposition and multidrug resistance in cancer

  2010cites this paper
• ABCB1: the role in Parkinson's disease and pharmacokinetics of antiparkinsonian drugs

  2009cites this paper
• Role of two efflux proteins, ABCB1 and ABCG2 in blood-brain barrier transport of bromocriptine in a murine model of MPTP-induced dopaminergic degeneration.

  2009cites this paper
• ABCB1:theroleinParkinson's diseaseandpharmacokineticsof antiparkinsoniandrugs

  2009cites this paper
• nteractions between antiparkinsonian drugs and ABCB 1 / P-glycoprotein t the blood – brain barrier in a rat brain endothelial cell model

  2008cites this paper
• Molecular modes of action of cytotoxic alkaloids: from DNA intercalation, spindle poisoning, topoisomerase inhibition to apoptosis and multiple drug resistance.

  2007cites this paper
• Interactions between the dopamine agonist, bromocriptine and the efflux protein, P-glycoprotein at the blood-brain barrier in the mouse.

  2006cites this paper
• Cancer cell permeability-glycoprotein as a target of MDR reverters: possible role of novel dihydropyridine derivatives.

  2006cites this paper
• Oxidative metabolism by P450 and function coupling to efflux systems: Modulation of mycotoxin toxicity

  2005cites this paper
• Synergistic effect of bromocriptine and tumor necrosis factor-alpha on reversing hepatocellular carcinoma multidrug resistance in nude mouse MDR1 model of liver neoplasm.

  2005cites this paper
• Prediction of oral drug absorption in humans by theoretical passive absorption model.

  2005cites this paper
• Synthesis and evaluation of dopamine D3 receptor antagonist 11C-GR218231 as PET tracer for P-glycoprotein.

  2005cites this paper
• ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal

  2005cites this paper
• Polymorphisms in Human MDR1 (P‐glycoprotein): Recent Advances and Clinical Relevance

  2004cites this paper
• An Enzymatic Microplate Assay for Testing P-Glycoprotein Substrates and Inhibitors

  2004cites this paper
• The reversal of multidrug resistance: an update.

  2003cites this paper
• The reversal of multidrug resistance: an update

  2003cites this paper
• Experimental estimation of the role of P-Glycoprotein in the pharmacokinetic behaviour of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco-2 cell model.

  2003cites this paper
• The medicinal chemistry of multidrug resistance (MDR) reversing drugs.

  2002cites this paper
• Interaction between lansoprazole and bromocriptine in a patient with Parkinson's disease.

  2002cites this paper
• Characterization of two pharmacophores on the multidrug transporter P-glycoprotein.

  2002cites this paper
• Bromocriptine Reverses P‐Glycoprotein‐mediated Multidrug Resistance in Tumor Cells

  2002cites this paper
• Inhibitors of multidrug resistance to antitumor agents (MDR).

  2002cites this paper
• Drugs as P-glycoprotein substrates, inhibitors, and inducers

  2002cites this paper
• Increase in doxorubicin cytotoxicity by inhibition of P-glycoprotein activity with lomerizine.

  2001cites this paper
• Erythromycin increases plasma concentrations of α‐dihydroergocryptine in humans

  2001cites this paper
• Plasma and urine pharmacokinetics of the dopamine agonist alpha-dihydroergocryptine in patients with hepatic dysfunction.

  2001cites this paper
• Recognition and oxidative metabolism of cyclodipeptides by hepatic cytochrome P450.

  2001cites this paper
• Role of dopamine in malignant tumor growth

  2000cites this paper
• Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins.

  2000cites this paper
• Multiple recognition of various amphiphilic molecules by the multidrug resistance P-glycoprotein: molecular mechanisms and pharmacological consequences coming from functional interactions between various drugs.

  1999cites this paper